dengu
viru
denv
member
genu
flaviviru
famili
flavivirida
caus
one
widespread
diseas
human
four
serotyp
dengu
viru
type
similar
clinic
manifest
epidemiolog
tropic
subtrop
region
world
wang
et
al
denv
attack
set
target
cell
includ
dendrit
cell
monocytesmacrophag
endotheli
cell
dissemin
cell
pagni
denv
enter
cytoplasm
rna
genom
directli
translat
singl
polyprotein
eventu
cleav
individu
viral
protein
includ
three
structur
protein
c
prm
e
seven
protein
chamber
et
al
filomatori
et
al
zybert
et
al
idre
ashfaq
dengu
infect
either
result
mild
ill
known
dengu
fever
df
sever
even
diseas
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
dss
guzman
kouri
current
estim
million
case
dengu
infect
occur
annual
swept
countri
potenti
spread
simmon
et
al
septemb
decemb
unexpect
larg
outbreak
dengu
infect
signific
proport
sever
case
report
pearl
river
delta
guangdong
provinc
china
sever
dengu
epidem
year
case
diagnos
includ
five
death
http
wwwcdcporgcn
emerg
unpreced
magnitud
dengu
outbreak
arous
widespread
social
concern
situat
consid
develop
effect
dengu
vaccin
high
prioriti
due
great
endeavor
scientif
research
around
world
dengvaxia
sanofi
pasteur
lyon
rh
becom
first
licens
vaccin
avail
prevent
df
howev
avail
antivir
agent
approv
combat
denv
idre
ashfaq
therefor
current
circumst
press
task
develop
safe
effect
antivir
drug
dengu
current
seri
natur
compound
deriv
report
import
sourc
antivir
drug
pompei
et
al
chen
et
al
fior
et
al
exampl
triterpen
compound
glycyrrhiz
acid
gra
glycyrrhetin
acid
gna
deriv
demonstr
block
replic
broad
spectrum
virus
includ
human
immunodefici
viru
hiv
sar
relat
coronaviru
viru
flavivirus
vesicular
stomat
viru
vsv
hepat
b
c
viru
influenza
viru
rotaviru
adenoviru
etc
dargan
et
al
b
takahara
et
al
matsuo
et
al
cinatl
et
al
cranc
et
al
lin
orlent
et
al
co
et
al
ashfaq
et
al
hardi
et
al
smirnov
et
al
carbenoxolon
disodium
cbx
one
gna
deriv
similar
substanc
found
root
licoric
plant
structur
cbx
clinic
appli
treatment
gastric
ulcer
type
inflamm
connor
besid
cbx
best
known
cellular
physiolog
effect
blocker
gap
junction
rozent
et
al
earlier
studi
cbx
report
exhibit
complex
activ
herp
simplex
viru
hsv
includ
synthesi
process
transport
viral
gene
product
dargan
dargan
et
al
nonetheless
whether
cbx
inhibitori
effect
denv
remain
unknown
studi
investig
whether
cbx
treatment
inhibit
dengu
infect
measur
product
progeni
virion
viral
rna
well
viral
protein
express
data
show
inhibit
progeni
virion
follow
treatment
indic
concentr
cbx
moreov
cbx
remark
abolish
viru
infect
decreas
viru
titer
furthermor
treatment
cbx
significantli
decreas
denv
rna
progeni
virion
supernat
result
first
time
identifi
old
drug
cbx
novel
compound
might
develop
potenti
treatment
dengu
infect
cell
atcc
cultur
dmem
gibco
carlsbad
ca
complement
fb
cell
atcc
cultur
gibco
fetal
bovin
serum
fb
hyclon
logan
ut
invitrogen
carlsbad
ca
huvec
cell
clonet
corp
san
diego
ca
cultur
medium
jrh
bioscienc
lenexa
ks
contain
fb
mgml
endotheli
cell
growth
supplement
collabor
biomed
product
bedford
mgml
heparin
sigma
st
loui
mo
mosquito
cell
line
cell
atcc
cultur
fb
media
supplement
sodium
pyruv
penicillin
uml
streptomycin
invitrogen
hawaii
strain
new
guinea
c
strain
provid
guangzhou
center
diseas
control
propag
cell
cell
inocul
denv
multipl
infect
moi
incub
day
day
supernat
collect
clarifi
centrifug
viru
titer
measur
assay
cell
viral
stock
store
vesicular
stomat
viru
vsv
kindli
provid
dongyan
jin
kok
et
al
propag
vero
cell
mtt
bromid
purchas
st
loui
mo
cell
cultur
plate
differ
concentr
cbx
hr
pb
contain
mtt
mgml
ad
well
hr
incub
supernat
remov
dmso
ad
well
solubil
formazan
crystal
absorb
measur
micropl
reader
nm
vigor
shake
adher
huvec
cell
seed
cell
cultur
plate
day
prior
infect
suspens
cell
line
cell
seed
day
infect
infect
denv
virion
dilut
dmem
huvec
without
fb
inocul
cell
monolay
suspens
moi
moi
hr
incub
allow
viru
attach
supernat
remov
cell
wash
three
time
pb
remov
residu
viru
infect
cell
incub
cultur
medium
contain
fb
indic
time
cbx
acid
purchas
dissolv
accord
product
instruct
appropri
volum
medium
contain
specif
concentr
cbx
ad
cell
differ
time
frame
start
hr
prior
denv
infect
hr
concurr
viral
infect
till
hr
hr
prior
viral
infect
till
hr
hr
prior
viral
infect
till
hr
cell
incub
indic
time
infect
harvest
total
rna
extract
purifi
cell
use
trizol
reagent
invitrogen
accord
manufactur
instruct
revers
transcript
carri
use
rna
quantit
pcr
reaction
perform
triplic
cdna
templat
use
iq
sybr
green
supermix
hercul
ca
perform
detect
system
mrna
express
level
normal
gapdh
express
primer
pair
use
follow
gapdh
dehydrogenas
forward
primer
gccttccgtgtccccactg
revers
primer
cgcctgcttcaccaccttc
gene
forward
primer
tcctaacaatcccaccaacagca
revers
primer
agttctgcgtctcctgttcaaga
cell
seed
onto
coverslip
confluenc
infect
moi
moi
hr
left
uninfect
cell
fix
paraformaldehyd
min
permeabil
pb
contain
triton
viru
protein
detect
use
monoclon
antibodi
denv
prm
glycoprotein
abcam
cambridg
secondari
antibodi
invitrogen
cell
nuclei
stain
dapi
stain
sampl
visual
use
zeiss
fluoresc
microscop
denv
titer
harvest
supernat
determin
assay
sampl
serial
dilut
inocul
cell
plate
incub
cell
examin
cytopath
effect
cpe
light
microscop
viru
titer
calcul
use
method
reed
muench
one
equival
pfuml
titer
vsv
quantifi
use
plaqu
assay
nineti
percent
confluent
vero
cell
plate
infect
optim
dilut
vsv
cover
low
melt
temperatur
agaros
sangon
biotech
shanghai
china
rins
phosphat
buffer
salin
pb
hr
crystal
violet
use
stain
vero
cell
plaqu
quantifi
suspens
contain
pfuml
suspens
contain
pfuml
incub
equal
volum
dmem
without
indic
concentr
cbx
indic
time
mixtur
dilut
dmem
use
infect
cell
test
viral
titer
cell
test
residu
infect
assay
immunofluoresc
assay
quantit
separ
set
assay
least
three
independ
experi
evalu
data
repres
mean
sd
statist
signific
determin
unpair
student
p
consid
statist
signific
chemic
structur
cbx
shown
figur
cytotox
cbx
first
determin
tetrazolium
bromid
mtt
method
cell
one
cell
establish
suitabl
dosag
studi
shown
figur
cell
viabil
close
control
treatment
cbx
wherea
cell
surviv
presenc
cbx
therefor
cbx
concentr
rang
consid
follow
assay
examin
effect
cbx
denv
infect
cell
infect
hawaii
strain
new
guinea
c
strain
respect
incub
hr
presenc
absenc
cbx
shown
figur
product
infecti
denv
particl
significantli
decreas
cbx
treatment
manner
concentr
cbx
treatment
led
reduct
titer
respect
fig
likewis
cbx
around
lower
level
titer
observ
control
respect
fig
taken
togeth
result
suggest
cbx
inhibit
effect
progeni
denv
product
cell
effect
cbx
limit
specif
denv
serotyp
determin
whether
cbx
inhibit
product
infecti
progeni
denv
cell
assay
perform
measur
viru
titer
huvec
cell
wide
use
denv
studi
halstead
wu
et
al
shown
figur
b
huvec
cell
well
infect
cell
infect
cell
treat
cbx
result
reduct
viru
titer
respect
fig
huvec
cell
treat
cbx
led
reduct
viru
titer
respect
fig
result
indic
activ
cbx
examin
effect
cbx
synthesi
denv
viral
rna
quantit
perform
shown
figur
b
viral
rna
c
protein
synthesi
affect
cbx
treatment
even
highest
concentr
meanwhil
immunofluoresc
assay
perform
analyz
effect
cbx
denv
viral
protein
express
upon
infect
antibodi
specif
denv
structur
prm
protein
use
part
studi
percentag
prm
contain
cell
calcul
determin
express
viral
protein
fig
f
shown
figur
e
cbx
treatment
highest
concentr
reduc
viral
protein
express
result
suggest
denv
viral
rna
synthesi
protein
express
regul
cbx
treatment
identifi
step
progeni
denv
product
inhibit
cbx
inhibitori
effect
analyz
experi
cell
cbx
ad
media
differ
time
frame
fig
start
hr
prior
denv
infect
hr
concurr
viral
infect
till
hr
hr
prior
viral
infect
till
hr
till
hr
cell
supernat
harvest
assay
shown
figur
cell
cbx
led
approxim
reduct
progeni
viru
titer
contrast
cbx
signific
impact
yield
fig
cbx
freeli
shuttl
cytoplasm
three
treatment
mention
park
connor
result
indic
inhibitori
effect
cbx
denv
exhibit
target
host
cell
elimin
cbx
media
hr
titer
progeni
particl
also
affect
fig
system
newli
form
virion
began
secret
cell
hr
data
shown
point
mention
prevent
progeni
virion
contact
cbx
therefor
result
studi
suggest
cbx
inhibit
denv
directli
target
infecti
virion
extracellularli
studi
direct
effect
cbx
denv
particl
suspens
differ
concentr
cbx
respect
indic
time
viral
titer
determin
assay
shown
figur
titer
significantli
decreas
incub
cbx
respect
cbx
suspens
incub
cbx
hr
respect
viru
titer
time
point
significantli
decreas
fig
likewis
cbx
exhibit
similar
behavior
shown
figur
treat
suspens
cbx
result
reduct
viru
titer
respect
moreov
longer
incub
cbx
correspondingli
led
lower
titer
residu
peak
hr
incub
fig
surprisingli
titer
almost
undetect
incub
cbx
hr
fig
taken
togeth
data
indic
incub
cbx
effect
decreas
denv
titer
manner
furthermor
directli
incub
cbx
hr
follow
infect
cell
indic
time
viral
rna
synthesi
viral
protein
express
progeni
viru
product
compar
indic
shown
figur
level
viral
rna
hr
bare
detect
cell
infect
control
cell
viral
rna
synthesi
gradual
increas
post
infect
fig
immunofluoresc
microscopi
imag
show
cell
posit
stain
denv
prm
glycoprotein
antibodi
group
compar
approxim
control
cell
posit
stain
hr
post
infect
fig
c
likewis
product
progeni
virion
group
dramat
decreas
fig
therefor
denv
infect
significantli
inhibit
cbx
data
figur
suggest
antivir
activ
cbx
denv
may
mainli
due
virucid
effect
exert
compound
test
assumpt
cell
infect
incub
hr
differ
concentr
cbx
supernat
collect
viru
rna
detect
shown
figur
rna
progeni
virion
supernat
significantli
decreas
cbx
treatment
manner
concentr
cbx
treatment
led
reduct
mrna
express
respect
fig
suggest
cbx
virucid
activ
inactiv
progeni
denv
particl
corrobor
virucid
effect
cbx
cell
infect
low
moi
hr
complet
least
two
replic
cycl
incub
cbx
till
end
infect
quantit
result
show
viral
rna
synthesi
significantli
decreas
group
fig
similarli
result
immunofluoresc
assay
show
cbx
treatment
led
effect
reduct
viral
protein
express
fig
percentag
prm
contain
cell
half
less
control
group
fig
taken
togeth
result
indic
cbx
inhibit
replic
progeni
denv
particl
virucid
activ
confirm
specif
antivir
activ
cbx
vsv
anoth
envelop
viru
evalu
vsv
suspens
differ
concentr
cbxm
respect
indic
time
viral
titer
determin
plaqu
assay
shown
figur
vsv
titer
significantli
decreas
incub
cbx
respect
cbx
vsv
suspens
incub
cbx
hr
respect
viru
titer
significantli
decreas
manner
fig
potent
inhibit
anoth
envelop
viru
vsv
indic
antivir
effect
cbx
specif
denv
current
epidem
dengu
infect
pose
threat
public
health
worldwid
make
clear
safe
effect
countermeasur
urgent
need
infect
unfortun
almost
specif
antivir
treatment
current
avail
dengu
diseas
given
complex
patholog
ill
need
control
four
viru
serotyp
simultan
dengu
vaccin
develop
challeng
respons
urgent
need
effect
drug
work
first
time
identifi
cbx
one
glycyrrhetin
acid
gna
deriv
potenti
natur
compound
differ
serotyp
denv
cbx
treatment
inhibit
rna
synthesi
protein
express
one
replic
cycl
markedli
reduc
progeni
viru
product
suggest
stage
denv
lifecycl
possibl
target
experi
also
perform
narrow
effect
period
compound
report
cbx
freeli
shuttl
cytoplasm
park
connor
howev
progeni
inhibit
cbx
ad
viru
attach
till
hr
throughout
cours
infect
cell
till
hr
indic
inhibit
cbx
exhibit
target
host
cell
result
deduc
denv
target
cbx
test
assumpt
virucid
activ
assay
perform
titer
residu
infect
denv
affect
assum
cbx
manifest
reduct
viral
rna
viral
protein
drop
viral
titer
studi
found
level
viral
rna
supernat
significantli
group
demonstr
cbx
directli
inactiv
progeni
denv
particl
via
virucid
activ
virucid
effect
cbx
denv
might
exert
irrevers
disrupt
viral
envelop
intact
viru
lose
protect
result
degrad
studi
use
three
differ
cell
line
huvec
investig
effect
cbx
denv
given
high
suscept
denv
cell
main
cell
line
use
cell
line
substitut
peripher
blood
mononuclear
cell
pbmc
mimic
vivo
infect
clyde
et
al
huvec
cell
cell
line
human
umbil
vein
endotheliocyt
also
test
repres
primari
cell
type
result
inhibit
increas
cbx
three
cell
line
demonstr
cbx
effect
inhibit
variou
cell
type
target
viru
besid
virus
also
use
verifi
inhibitori
effect
cbx
result
demonstr
antivir
activ
cbx
specif
cell
type
denv
serotyp
might
predict
cbx
new
compound
exhibit
favor
applic
perspect
previou
studi
show
glycyrrhizin
anoth
effect
compound
deriv
glycyrrhiza
inhibit
denv
infect
vero
cell
cranc
et
al
promot
us
suppos
cbx
one
deriv
glycyrrhetin
acid
gna
may
play
effect
role
infect
observ
studi
cbx
treatment
significantli
reduc
progeni
viru
yield
differ
serotyp
denv
studi
found
cbx
inhibit
denv
infect
virucid
activ
besid
denv
cbx
previous
found
inhibit
anoth
viru
hsv
partridg
poswillo
dargan
howev
antivir
mechan
cbx
two
virus
quit
distinct
regard
hsv
cbx
appear
activ
throughout
replic
cycl
reduc
synthesi
polypeptid
affect
transport
certain
protein
inhibit
process
result
cbx
treatment
greatli
diminish
progeni
hsv
qualiti
thought
inhibit
hsv
infect
manner
alter
cellular
activ
affect
viru
replic
activ
host
antivir
mechan
model
cbx
directli
inhibit
infect
denv
particl
without
target
host
cell
likewis
studi
found
cbx
significantli
decreas
vsv
titer
taken
togeth
suggest
antivir
activ
cbx
limit
specif
type
viru
mechan
might
someth
differ
point
cbx
wide
use
compound
inhibitor
gap
junction
connor
gap
junction
intercellular
commun
rout
genet
studi
reveal
connexin
cx
protein
molecular
compon
vertebr
gap
junction
channel
paul
gap
junction
compris
cluster
transcellular
channel
allow
small
signal
molecul
inorgan
ion
transfer
rapidli
directli
one
cell
anoth
recent
studi
report
gap
junction
play
key
role
physiolog
process
patholog
condit
sever
virus
hiv
cytomegaloviru
cmv
borna
diseas
viru
rou
sarcoma
viru
eugenin
importantli
order
increas
viru
product
infect
latter
two
virus
result
cx
express
gap
junction
blocker
cbx
inhibit
variou
cx
protein
includ
tonkin
et
al
therefor
possibl
cbx
inhibit
denv
infect
block
cx
protein
could
rule
end
much
work
would
need
elucid
exactli
cbx
inactiv
denv
virucid
activ
studi
suitabl
anim
model
would
also
requir
evalu
reproduc
inhibitori
effect
cbx
vivo
conclus
work
provid
compel
data
cbx
inhibitori
effect
denv
infect
importantli
antivir
activ
cbx
limit
specif
cell
type
specif
denv
serotyp
combin
histori
clinic
treatment
gastric
ulcer
inflamm
good
safeti
profil
turpi
thomson
ram
et
al
cbx
might
potenti
develop
promis
antivir
drug
dengu
infect
